FH is altered in 40.0% of hereditary leiomyomatosis and renal cell cancer patients [2].

FH is an inclusion eligibility criterion in 3 clinical trials for hereditary leiomyomatosis and renal cell cancer, of which 2 are open and 1 is closed. Of the trials that contain FH status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 3 are phase 2 (2 open) [3].

SDHA is an inclusion eligibility criterion in 1 clinical trial for hereditary leiomyomatosis and renal cell cancer, of which 0 are open and 1 is closed. Of the trial that contains SDHA status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 1 is phase 2 (0 open) [3].

SDHB is an inclusion eligibility criterion in 1 clinical trial for hereditary leiomyomatosis and renal cell cancer, of which 0 are open and 1 is closed. Of the trial that contains SDHB status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 1 is phase 2 (0 open) [3].

SDHC is an inclusion eligibility criterion in 1 clinical trial for hereditary leiomyomatosis and renal cell cancer, of which 0 are open and 1 is closed. Of the trial that contains SDHC status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 1 is phase 2 (0 open) [3].

SDHD is an inclusion eligibility criterion in 1 clinical trial for hereditary leiomyomatosis and renal cell cancer, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 1 is phase 2 (0 open) [3].